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1. INTRODUCTION 
Well over 200 viruses are known to be pathogenic to humans (Bibby, 2013). New viruses have 
traditionally been identified based on the patient symptoms combined with methods such as: viral 
culture, electron microscopy, serology, cytology and histology. These techniques are effective but 
have certain limitations. For example, not all viruses can be cultured in laboratory conditions and 
some of the traditional techniques can be time consuming (Storch, 2007). Rapid developments in the 
fields of sequencing, bioinformatics and metagenomics have revolutionized the discovery of novel 
human viruses. With the high-throughput sequencing methods it is possible to gain extensive amounts 
of sequence data, simultaneously. Viral metagenomics is a technique where the whole viral nucleotide 
sequence content (virome) (Bexfield & Kellam, 2011) of an uncultivated sample, e.g. from marine 
environments (Breitbart et al., 2002) or human blood (Jones et al., 2005), can be sequenced and 
analyzed.  
Due to high-throughput sequencing and metagenomics, several putative human pathogens have been 
found in the last fifteen years:  Karolinska Institutet (KI) polyomavirus, human bocavirus 1 (HBoV1), 
astrovirus VA1, Washington University (WU) polyomavirus, Lujo virus, trichodysplasia spinulosa 
polyomavirus and human parvovirus (PARV4) (Allander et al., 2007; Allander et al., 2005; 
Finkbeiner et al., 2009; Gaynor et al., 2007;  Briese et al., 2009; Janssens et al., 2010; Jones et al., 
2005). Among the newly discovered viruses are also members of the parvovirus family. Bufavirus 
(BuV), Tusavirus (TuV) and cutavirus (CuV), have been identified in recent years during viral 
metagenomic studies (Phan et al., 2014; Phan et al., 2012; Phan et al., 2016). The clinical significance 
of TuV, BuV and CuV is yet to be unraveled and more research is needed to clarify their 
pathogenicity. With new viruses being discovered at a faster rate than before, the need for assessing 
their clinical significance and the need for rapid diagnostics will become even more important (Tang 
& Chiu, 2010). In the following chapters I will describe the family Parvoviridae and BuV, TuV and 
CuV in more detail. I will also describe the theory behind the main methods used in this work.  
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1.1. Family Parvoviridae 
Parvoviruses are among the smallest known viruses when it comes to the size of the virion and the 
size of the genome. The size of the virion is approximately 25 nanometers (nm) in diameter (Berns 
& Parrish, 2013) and the genome is a  linear single-stranded DNA (ssDNA) with an average size 
around 5 kilobases (kb) (Cotmore & Tattersall, 2014). Despite the small size of the genome and the 
particle itself, parvoviruses are a diverse group of viruses able to infect hosts from cats to humans to 
cockroaches (Bowles et al., 2006; Mukha et al., 2006; Cotmore et al., 2019). The family Parvoviridae 
is divided into two subfamilies based on the host: viruses that belong to Densovirinae infect 
invertebrates and viruses from Parvovirinae infect vertebrates (Cotmore et al., 2014). Based on the 
sequence and phylogenetic analyses, five parvovirus genera are grouped into Densovirinae subfamily 
and eight genera into Parvovirinae  subfamily (Figure 1) (Cotmore et al., 2019; Cotmore & Tattersall, 
2007).  As of October 2018, there were 58 International Committee on Taxonomy of Viruses (ICTV) 
approved species in the Parvovirinae subfamily. 
 
 
Figure 1. Taxonomy of the Parvoviridae family, subfamilies Densovirinae and Parvovirinae and all 
the Parvovirinae genera with a few example species. Tusavirus (marked in red) is still an unclassified 
member of genus Protoparvovirus (Cotmore et al., 2019).  
 
The parvovirus capsids are rugged, non-enveloped icosahedrons with T=1 symmetry, consisting of 
60 copies of 1-3 structural proteins (VP1-VP3) (Berns & Parrish, 2013). The ∼5 kb genome usually 
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consists of two major genes, non-structural (NS) and structural (VP), which are regulated by one or 
more promoters (Figure 2), depending on the virus. The NS gene encodes a multipurpose protein NS1, 
which regulates the viral cycle on different levels. NS1 is essential in regulation of viral gene 
expression through activation of parvovirus promoters, DNA replication (Zhi et al., 2006), and 
transactivation of host genes (Lou et al., 2012). NS1 has DNA-binding and nicking domains (Op De 
Beeck & Caillet-Fauquet, 1997) and cytotoxic properties (Hristov et al., 2010) inducing apoptosis 
(Moffat et al., 1998). The VP gene encodes one long capsid protein (VP1) and different length 
variants by alternative splicing (VP2-VP5), depending on the virus (Cotmore & Tattersall, 2014; Qiu 
et al., 2017). BuV, TuV and CuV genomes encode two major genes: NS and VP. The two genes 
translate to three major proteins NS1, VP1 and VP2, of which VP1 and VP2 by alternative splicing 
(Väisänen et al., 2017, Altay et al., 2015, Phan et al., 2014). 
The parvovirus ssDNA strand is distinctively flanked by two short imperfect palindromic sequences. 
The flanking sequences can fold back in both termini of the DNA sequence creating terminal loops 
or hairpins (Figure 2) and play a great role in parvovirus replication. Parvoviruses replicate using a 
unique mechanism called “rolling hairpin”, described already in 1976 (Tattersall & Ward, 1976). The 
rolling hairpin is an adaptation of the rolling-circle replication system ( Li, 2013) used by bacteria for 
plasmid replication and by many circular dsDNA (double-stranded DNA) viruses for genome 
replication (Ruiz-Maso et al., 2015). The hairpins act as primers for the complementary strand during 
replication (Berns & Parrish 2013). The synthesis of the complementary strand is dependent on host 
polymerases and the elongation is followed by complicated series of folding back and forth before 
the new DNA strand is ready (Cotmore and Tattersall, 2014).  
 
The hairpin structures are diverse among members of Parvoviridae and can differ in size, sequence 
and structure (Deiss et al., 1990; Li, 2013). For example, HBoV1 and parvovirus B19 (B19V) have 
hetero- and homotelomeric hairpin structures, respectively (Astell et al., 1989; Huang et al., 2012; 
Luo & Qiu, 2015). The hairpin structures for BuV, TuV and CuV are unknown, but are thought to be 
similar to other protoparvoviruses e.g. minute virus of mice (MVM) (Figure 2) (Väisänen et al., 
2017). 
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Figure 2. A simplified illustration of a typical parvovirus (minute virus of mice) genome organization 
showing the terminal hairpin structures and the two promoters, indicated by two curved arrows. The 
left side encodes the non-structural (NS) region and the right side for structural (VP) region (Cotmore 
and Tattersall, 1986; Cotmore et al., 2019).  
 
Parvoviruses are transmitted through various routes: via the respiratory route (B19V and HBoV1) 
(Qiu et al., 2017), via intrauterine transmission and blood-products (B19V) (Brown, 2006), via the 
fecal-oral route (canine parvovirus and feline parvovirus) (Parrish & Hueffer, 2006). Parvoviruses 
lack proteins capable of inducing resting cells to enter an interphase. Infections are limited to dividing 
cells (Cotmore and Tattersall, 2013), except for HBoV1 which can replicate in non-dividing human 
epithelial cells with the help of the cellular DNA damage response and repair system (Deng et al., 
2016; Huang et al., 2012). Parvoviruses enter the host cell by binding to specific cell surface receptors 
and by receptor mediated endocytosis (Vihinen-Ranta et al., 2002; Vihinen-Ranta & Parrish, 2006). 
When entering the cell, the virion undergoes conformational changes which result in exposure of a 
phospholipase A2 (PLA2) motif in VP1 (Bleker et al., 2005; Farr et al., 2005) at the capsid surface 
(Vihinen-Ranta et al., 2002).  
Not a lot is known of parvovirus intracellular traffiking, but it is suggested that PLA2 activity is 
utilized during intracellular traffiking and is resposible for damaging the late endosome prior to 
nuclear entry (Farr et al., 2005, Zadori et al., 2001). After nuclear entry parvoviruses hi-jack the host 
replication system. How parvoviruses utilize the host replication system, is not fully understood. A 
recent study shows that B19V can alter the cell signalling pathways and induce cell cycle arrest 
resulting in a prolonged S-phase (Zou et al., 2017). During the prolonged S-phase the virus can utilize 
the host replication system for viral replication. The produced mRNA is translated on cellular 
ribosomes in the cytoplasm and the structural proteins are transported back to the nucleus as trimers 
(Lombardo et al., 2002), where the virions are assembled and new genomes are encapsidated. The 
virions are released by inducing apoptosis at the end of the infection (Moffatt et al., 1998; Schmidt 
et al., 2002). Release of progeny virus prior to apoptosis has been described for MVM and HBoV1 
(Deng et al., 2013; Maroto et al., 2004). The rapid export pathway utilizes the nuclear export protein 
CRM1 and transport through the Golgi (Bär et al.,  2013).  
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1.1.1. A short history of parvoviruses 
The first discovered parvovirus (lat. parvus = small) was the Kilham rat virus (KRV) in 1959 isolated 
from a rat tumor (Kilham & Olivier, 1959). KRV has been extensively studied and it is now known 
that the virus is widely spread in rodents and can cause fetal death or trigger autoimmune diabetes in 
rats (Chung et al., 2014; Ellerman et al., 1996). Atchinson et al. (1965) found small virus-like 
particles from rhesus monkey kidney cell cultures infected with simian adenovirus type 15, they 
referred to the newly found particle as adenovirus associated virus (AAV). AAV was later identified 
as parvovirus and further studies have shown that AAV can infect humans but is non-pathogenic (Qiu 
et al., 2017). These qualities make AAV a very interesting candidate for gene therapy. AAV is 
intensively studied as a viral vector and some clinical trials of using AAV in gene therapy are already 
taking place (Rangarajan et al., 2017).  
 
Figure 3. Parvovirus timeline from the discovery of KRV, the founding member of the Parvoviridae 
family, to the year 2016, when CuV, an emerging human protoparvovirus, was discovered.  
 
B19V was found in 1975 (Cossart et al.,1975) in human sera. B19V infections are very common 
especially among children and appear as a rash also called fifth disease (erythema infectiosum) 
(Anderson et al.,1983). Maternal B19V infection can cause fetal death, if the infection is acquired 
during the first months of pregnancy (Brown et al., 1984). In 1975 the Parvoviridae family was 
officially accepted by ICTV (ICTV, 1975). Three decades passed until a new human pathogenic 
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parvovirus was found (Figure 3). Human bocavirus 1 (HBoV1) and PARV4 were both identified in 
2005 (Allander et al., 2005; Jones et al., 2005) in viral metagenomics studies. HBoV1 was found in 
respiratory tract samples of a young child with symptomatic respiratory tract infection. After 2005, 
three additional human bocaviruses (HBoV2-4) were discovered, all in diarrheic stool samples 
(Kapoor et al., 2009, Arthur et al., 2009; Kapoor et al., 2010). HBoV1 is strongly linked to respiratory 
tract infections, especially among young children (Allander et al.,2007; Maggi et al., 2007; Zheng et 
al., 2010), whereas for HBoV2-4, the clinical pictures are unclear. HBoV2-4 are mainly detected 
from stool samples (Santos et al., 2010, Kantola et al.,2011) and there is some evidence linking these 
viruses to gastrointestinal infections (Arthur et al., 2009). PARV4 was first identified in a plasma 
sample of intravenous drug user, with symptoms of acute viral syndrome (Jones et al.,2005). PARV4 
infection is strongly associated with other viral infections, such as human immunodeficiency virus, 
hepatitis C or hepatitis B (Matthews et al., 2014). The clinical significance and definitive symptoms 
of PARV4 are still unclear (Sharp et al., 2010). After 2010, three novel putative human pathogenic 
parvoviruses have been discovered: BuV, CuV and TuV (Phan et al., 2014; Phan et al., 2012; Phan 
et al., 2016).  
1.2. Emerging human protoparvoviruses 
1.2.1. Bufavirus is the most reported new Protoparvovirus  
During a metagenomics project in 2012, a virus resembling parvovirus was found in a fecal sample 
collected from a child suffering from acute diarrhea in Burkina Faso (Phan et al., 2012). This newly 
found virus shared an amino-acid sequence identity of <39% in NS1 and <31% in VP1 with known 
parvoviruses. The parvovirus-like sequence was detected by PCR in 4% of the analysed samples 
(4/98) (Phan et al., 2012). One of the discovered viruses shared only >73% amino acid identity in the 
VP2 with the other three virus sequences, indicating it was a different genotype. The viruses were 
named bufavirus 1 (BuV1) and bufavirus 2 (BuV2) and listed in GenBank with accession numbers 
JQ918261 and JX027297, respectively. Bufavirus 3 (BuV3) was initially identified in 2014 in Bhutan 
(Yahiro et al., 2014). The virus was found in 0.8 % (n=393) of stool samples collected from children 
with diarrhea (age >5 years). No other virus known to cause diarrhea was discovered in the BuV-
positive samples (Yahiro et al., 2014). According to ICTV parvoviruses in the same species must 
share over 85 % of amino acid identity in the NS1 (Cotmore et al., 2014). Phylogenetic analyses show 
that all three BuV genotypes share high amino acid sequence identities in the NS1 protein (Figure 4) 
and can consequently be classified in one species: Primate protoparvovirus 1.   
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Figure 4. Molecular phylogenetic analysis of a group of parvoviruses by the maximum likelihood 
method based on the virus NS1 gene nucleotide sequence. For the phylogenetic analyses traditional 
examples of parvoviruses were chosen as well as strains of emerging parvoviruses that had, if 
possible, full-length sequences of NS1 and VP1 regions available in GenBank 
(https://www.ncbi.nlm.nih.gov/genbank/). The maximum likelihood method is based on the Tamura-
Nei model (Tamura & Nei, 1993). The tree was generated with 1000 bootstraps and is drawn to scale, 
with branch lengths measured in the number of nucleotide substitutions per site. The percentage in 
which the taxa is clustered is shown next to the branches. The nucleotide sequences were aligned with 
ClustalW with open gap penalty of 10 and gap extension penalty of 0.1. Evolutionary analyses were 
conducted in MEGA7 (Kumar et al.,2016).    
 
Since the first discovery in 2012, BuV DNA has been detected by PCR primarily in fecal samples in 
Finland, the Netherlands, Thailand, Tunisia, Turkey and also in one nasal swab sample in Finland 
(Väisänen et al., 2014; 2018, Chieochansin et al., 2015, Smits et al., 2014,  Altay et al., 2015). These 
findings suggest that the virus is widely spread. Enzyme immunoassay (EIA) has been developed for 
all three BuVs (Väisänen et al., 2016). Väisänen et al. (2018) discovered that the BuV 
immunoglobulin G (IgG) antibody seroprevalence is significantly high in adults in Iran (56.1 %), Iraq 
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(84.8 %) and Kenya (72.3 %), while the seroprevalence is very low in Finland (1.9 %) and in the 
United States (3.6 %). This suggests that there are considerable differences in BuV distribution on a 
global level.  
 
1.2.2. Cutavirus is linked to cutaneous T-cell lymphoma 
Cutavirus was first discovered in 2016 during another metagenomics study (Phan et al.,2016). Two 
nearly full-length viral sequences resembling the BuV sequence were obtained from stool samples of 
two (n=245) Brazilian children suffering from diarrhea (CutaV-BR-337 and -450, GenBank accession 
no. KT868811 and KT868812, respectively). The group compared the gained sequences to existing 
metagenomic data and found corresponding sequences from skin biopsies of two patients with 
cutaneous T-cell lymphoma (CTCL), suggesting a possible connection to cancer. Results were 
confirmed with PCR and by sequencing (Phan et al., 2016). Based on sequence analysis, the 
discovered CuVs shared amino-acid identities of 76% and 82% in the NS1 and VP1 proteins, 
respectively, with BuV2 (Phan et al., 2016).  
In the past few years CuV has been detected mainly using PCR-based methods. CuV DNA was 
detected in a cutaneous malignant melanoma lesion sample in Denmark (CutaV CGG5–268, 
GenBank accession no. KX685945) (Mollerup et al.,2017) and in 6/189 (3.2%) paraffin-embedded 
skin biopsy samples of CTCL patients (Kreuter et al., 2018) by PCR. Kreuter et al. (2018) did not 
observe CuV DNA in skin samples of patients with other forms of lymphomas. Väisänen et al. (2018) 
detected CuV DNA by PCR in 4/25 (16%) and in 4/136 (2.9%) skin biopsies of CTCL patients and 
organ transplant patients, respectively, whereas 159 healthy skin samples from 98 immunocompetent 
healthy individuals were CuV-DNA negative. Furthermore, Väisänen et al. found CuV IgG 
antibodies in serum samples of the same groups: CTLC patients (9.5%), organ transplant patients 
(6.5%) and in healthy adults (3.8%). Based on these studies, there seems to be a strong association of 
CuV with CTCL. 
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Figure 5. Molecular phylogenetic analysis of a group of parvoviruses by the maximum likelihood 
method based on the virus VP2 gene nucleotide. The maximum likelihood method is based on the 
Tamura-Nei model (Tamura & Nei, 1993). The tree was generated with 1000 bootstraps and is drawn 
to scale, with branch lengths measured in the number of nucleotide substitutions per site. The 
percentage in which the taxa is clustered is shown next to the branches. Sequences were aligned with 
ClustalW with open gap penalty of 10 and gap extension penalty of 0.1. Evolutionary analyses were 
conducted in MEGA7 (Kumar et al.,2016).    
1.2.3. Tusavirus has been found in only one fecal sample 
Tusavirus, corresponding to Tunisian stool-associated parvovirus, was found in Tunisia in 2014 
during a metagenomic study (Phan et al., 2014). A near full-length sequence of 4424 bp (GenBank 
accession no. #KJ495710) was obtained from a stool sample of a small child suffering from 
unexplained diarrhea. When comparing the sequence with those of other parvoviruses, TuV is more 
closely related to rodent parvoviruses than to BuV or CuV or other human parvoviruses (Figures 4 
and 5). Väisänen et al. (2016 and 2018) reported low levels of TuV IgG in two serum samples of a 
young child and an adult in Finland. Further studies are needed to confirm if TuV is a true human 
virus.  
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1.3. Principles of qualitative polymerase chain reaction  
Polymerase chain reaction (PCR) was invented in 1983 by Kary Mullis (Mullis, 1990) and once the 
technology was optimized, it completely revolutionized the world of molecular biology. PCR enables 
exponential amplification of a specific segment of DNA with very high sensitivity and specificity. 
PCR is based on the DNA molecule’s unique nucleotide pairing (A-T and G-C) as well as the ability 
of the DNA strand to denature and anneal when the temperature is changed. PCR has undisputed 
attributes when compared to other pathogen identification methods analyzes can be performed within 
a few hours, it is highly specific and sensitive, it is widely commercialized and the reagents for 
standard PCR are relatively inexpensive. PCR is a high-throughput method where multiple samples 
can be analyzed to detect at least three pathogens simultaneously. However, PCR has a few 
drawbacks. To avoid contamination and false positive results, several precautions need to be taken 
when performing the assay. All reagents and plastics have to be PCR-sterile and usually several rooms 
are needed: one for master mix preparation and one for sample handling.  
PCR is an effective tool in pathogen DNA detection especially in clinical diagnostics, where speed, 
specificity and sensitivity are crucial. PCR-based methods are widely used in hospital laboratory 
diagnostics in Finland to detect viral and bacterial DNA in patient samples (Hus.fi, 2019). PCR-based 
techniques are extensively utilized in genomic studies, epidemiology, causal connections and 
distribution of pathogens etc.  
1.2.1. Quantitative PCR and hydrolysis probe technology 
Real-time quantitative PCR (qPCR) is based on the traditional PCR method, but real-time qPCR 
allows a real-time quantification of the sample by means of a standard curve and probe. There are 
two major qPCR technologies: the so-called dye-based method and probe-based methods. In the dye-
based methods the dye, such as SYBR Green, is added to the master mix. The dye binds to double-
stranded DNA and emits a fluorescence signal. The problem with dye-based methods is the lack of 
target specificity. The probe-based methods rely on a probe designed specifically to bind the desired 
target sequence. In this work the hydrolysis-based TaqMan probe format was used. The TaqMan 
probe is a nucleotide strand from 18 to 30 nucleotides in length, labeled with a fluorophore at the 5’ 
and with a quencher in the 3’ end. Simplified, when both fluorophore and quencher are attached to 
the nucleotide strand, no or very little fluorescence is detected. The quencher suppresses the 
fluorescence emitted by the fluorophore via fluorescence resonance energy transfer (FRET) when the 
two molecules are in proximity. If the probe is hybridized to the target sequence and DNA polymerase 
extends the primer, the probe is hydrolyzed, and the fluorophore is released, whereby the fluorescence 
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signal can be detected (Figure 6). TaqMan probe is especially beneficial in multiplex qPCR methods, 
where several individual targets can be detected in a single reaction. 
 
 
Figure 6. Simplified illustration of TaqMan® probe-based PCR assay. Both primer (pink arrow) and 
probe (green strand) hybridize with the complementary DNA strand. The quencher (Q) suppresses 
fluorescence when quencher and fluorophore are in proximity. Once DNA polymerase extends the 
primer, the probe is hydrolyzed, and the fluorophore is released into the reaction mix. The strength 
of the detected signals corresponds to the amount of amplified sequences.  
 
The BuV, CuV, TuV multiplex qPCR is based on the absolute quantification with a standard curve 
to calculate the quantity of the viruses in each sample. Absolute quantification is based on the standard 
curve, which in this case is produced by a dilution series of a plasmid containing the genome region 
of interest, where the copy number of each plasmid is known in each dilution. The quantification 
cycle value or Cq value, is the number of cycles that a certain specimen requires to reach the 
fluorescence threshold value. In this case the standard curve is a plot of the Cq values from each 
dilution (100 to 106) and the number of copies assigned to each standard dilution. The number of viral 
genome copies in each specimen can then be calculated based on the sample’s Cq value in qPCR.  
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1.4. Principles of IgM EIA 
Immunoglobulins or antibodies are proteins secreted by B-cells of the adaptive immune system. 
Antibodies are activated during viral infection, when an unknown molecule, an antigen, enters the 
host. Human antibodies are grouped into five primary classes based on the structure, location and 
function. IgA is present in mucous membranes and inhibits pathogen adhesion. IgE is involved in 
allergies and parasite infections. IgD is expressed on the surface of B-cells and is co-expressed with 
the transient IgM. IgG has multiple functions such as: neutralizing pathogens, immunity and 
involvement in secondary immune responses. IgM is often the first response when a new antigen is 
introduced and can quickly activate the complement. In immunoglobulin class switch, the antibody-
producing B-cells can switch the class of Ig it produces, from IgM to IgG (Hedman et al., 2011). IgG 
EIA has been developed for CuV, BuV and TuV (Väisänen et al., 2016; 2018), to study past infections 
and acquired immunity in individuals as well as seroprevalence in different populations. In the 
literature, there are no reports on IgM EIA to study acute CuV, BuV or TuV infections. 
The enzyme-linked immunosorbent assay (ELISA), or EIA, was first described in 1971 by two 
groups of scientists. Engvall & Perlmann (1971) and Van Weemen & Schuurs (1971) published 
papers describing the very first EIA techniques. Today EIA is a technique widely used both in 
research and in diagnostics. For example, in Helsinki University Hospital laboratory (HUSLAB) 
several EIA-based assays are used in virus and bacterial diagnostics to detect acute or past infections 
(Hus.fi, 2019). EIA is based on a few basic principles: covalent binding of the antigen or antibody to 
a solid surface, the exclusive antigen-antibody bond and the detection of antigen-antibody binding 
through color change.  
1.4.1. µ-capture IgM EIA 
The µ-capture EIA format is considered to be more sensitive and specific when compared to the 
direct-EIA format (Wreghitt and Sillis, 1985). In µ-capture EIA the capture antibody (anti-human 
IgM) is immobilised onto the plastic surface e.g. microtiter plate. The IgM antibodies present in the 
serum sample bind to the immobilized anti-human IgM. When the biotin labelled antigen is applied, 
it binds to the corresponding specific antibody (IgM antibody against the virus of interest). When 
horseradish-peroxidase (HRP) -conjugated streptavidin is added to the mix, it forms a strong non-
covalent bond with biotin. A substrate is then added to oxidise the HRP enzyme, resulting in a color 
change. The reaction is then stopped with an acid. The strength of color is directly proportional to the 
amount of IgM antibodies against the specific antigen in the sample and can be measured with a 
spectrophotometer. The scheme of µ-capture EIA is presented in Figure 7. 
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Figure 7. Principle of µ-capture EIA presented in a single microtiter well.  
 
Another variant of µ-capture EIA is µ-capture EIA with competition. The competition assay can be 
used to confirm the positive results of the µ-capture EIA and to rule out cross-reactivity of serum 
antibodies or background. In competition EIA, the biotinylated and the non-biotinylated antigen 
competitively bind the antibody (IgM) in the serum. Whether the aim is to verify positive result or to 
eliminate the possibility of cross-reactivity, the competition assay can be performed with homologous 
or heterologous antigens. The non-biotinylated antigens are applied in higher concentrations 
compared to the biotinylated antigens, to maximise the binding of the non-biotinylated antigen. If 
specific antibodies are present in the sample, the non-biotinylated antigen will bind. Thus, no signal 
can be detected, since non-biotinylated antigens block the binding sites and the HRP conjugated 
streptavidin is not able to bind to the non-biotinylated antigen.  For example, if the aim is to verify a 
positive result from µ-capture EIA, the competition assay can be done by competing the sample 
antibodies with homologous biotinylated and non-biotinylated antigens. If the non-biotinylated 
antigen binds to the sample, no signal is be detected and the sample can be deemed as positive.  
Several factors in the EIA can be optimized: serum dilution, antigen dilutions, substrate incubation 
time, purity of antigen, used plastics etc. The optimization efforts are more carefully described in 
materials and methods.    
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2. AIMS OF THE THESIS WORK 
 
There were two main aims in this thesis work:  
• To develop and optimize a protoparvovirus IgM µ-capture EIA assay using BuV1 as an 
example virus. If successful, this assay could be applied for other human protoparvoviruses 
as well. IgM EIA could be used to find acute protoparvovirus infections and further on 
investigate the symptoms caused by these viruses in acute infections.   
• To screen three patient cohorts for BuV, TuV and CuV DNA with in-house multiplex qPCR 
to assess viral DNA prevalence within these cohorts and to investigate the distribution of 
these viruses further.  
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3. MATERIALS AND METHODS 
Two main methods were used in the experimental phase of this thesis work: qPCR and IgM µ-capture 
EIA.  
3.1. Patient cohorts and sample preparation 
Stool or serum samples from four different patient cohorts were used in this study. The cohorts are 
described in Table 1. The HUSLAB v and b cohorts are collections of fecal samples sent to HUSLAB 
for norovirus PCR screening and for bacterial PCR screening, respectively. The age range of the 
patients in both HUSLAB cohorts varied from 0 to 99, mean age 55 years. Both of the HUSLAB 
cohorts have been previously used and described in (Väisänen et al., 2014). There were 56 samples 
available from the HUSLAB v cohort and 172 samples from the HUSLAB b cohort. HUSLAB v and 
b have already been screened for BuV DNA, so only TuV and CuV DNA were screened with duoplex 
qPCR. The received samples of the Malawi cohort, a collaboration with Per Ashorn from University 
of Tampere, were purified DNA of fecal samples collected from children 6 or 18 months of age in 
Malawi for a Child Nutrition Intervention Study (LCNI-5). Some of the samples had dried during 
storage or there were not enough sample to reach the required 5 µL pipetting volume. In these cases, 
5-10 µL of PCR-grade H2O was added to the sample tube. All stool samples were analyzed in 
replicates in the multiplex or duplex qPCR, if possible. All the samples were stored at -20 °C.  
 
Table 1. Patient cohorts used in the qPCR and/or BuV1 IgM µ-capture-EIA. HUSLAB v and b and 
MALAWI cohorts were used for BuV, TuV, and CuV -multiplex. The IRAN cohort was used setting 
up the BuV1 IgM µ-capture-EIA 
Cohort ID Age Number and type 
of samples 
Previously described in literature 
HUSLAB v Range: 0-99, 
median: 55 years 
56 
Stool 
Väisänen et al., 2014 
HUSLAB b Range: 0-99, 
median: 55 years 
172 
Stool 
Väisänen et al., 2014 
Malawi 6-18 months 179 
Stool 
No 
Iran Range: 1-77 
Median 38 years 
118 
Serum 
Väisänen et al., 2018 
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The samples for the µ-capture IgM EIA consisted of 118 serum samples from Iran, 107 of which were 
from healthy adults and 11 from children ≥18 years old, with no reported sicknesses. The serum 
samples were collected in Iran at the Hamadan Blood Transfusion Organization (Hamadan, Iran) and 
the cohort has been previously described in Väisänen et al., 2018. Samples were collected during the 
years 2015 and 2016 and the age range of the blood donors varied from 1 to 77 years, mean age 39 
years. The Iranian cohort was chosen due to the high IgG seroprevalence (over 50 %) for BuV1 
(Väisänen et al., 2018).  
3.1.2. Phenol-chloroform-based DNA extraction  
To validate the IgM-positive EIA results, the serum samples were also studied for BuV DNA by 
qPCR. For detection of viremia in serum, DNA was extracted from samples which gave over 0.220 
absorbance value in the IgM µ-capture assays without blocking (n=40). Phenol-chloroform extraction 
was chosen, since with this method it is possible to use extremely small amounts of sample material. 
For the initial extraction step 20 µL of serum, 2 µL of Proteinase K (Thermo Fischer) and Proteinase 
K buffer were combined and incubated for 30 minutes at +37°C. After incubation, 300 µL of phenol 
(WVR, pH 8.0) and 200 µL of PCR-grade H2O was added and the mixture was shortly vortexed and 
then centrifuged for 2 minutes at 13 000 rpm. The upper phase containing the DNA was transferred 
into a new microtube and 300 µL of chloroform was added, the mixture was vortexed and centrifuged 
for 2 minutes at 13 000 rpm. The upper phase was again transferred into a fresh microtube and sodium 
acetate pH 5.3 was added to a ratio of 1:10. Finally, 1 ml of ice-cold ethanol (WVR) was added and 
the mixture was shaken vigorously and stored frozen at -20 ºC for approximately 16 hours. After 
freezing the tubes were centrifuged for 30 minutes at +4 °C with 13 000 rpm. The liquid was carefully 
removed, and the pellet was dried in a laminar hood. After drying the pellet was suspended into PCR-
grade H2O. The purified DNAs were stored at -20 °C.  
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3.2.  Multiplex qPCR 
An in-house multiplex real-time qPCR for BuV, TuV and CuV has been previously established and 
published (Väisänen et al. 2018). The sensitivity and specificity of the assay is 10 copies of viral 
DNA/µL with no cross-reactivity between human DNA, B19V, HBoV1-4, PARV4 or 13 human 
polyomaviruses (Väisänen et al., 2018). All samples were analyzed with Agilent Technologies 
AriaMX real-time qPCR device using disposable 96-well plates (4ti-0740. 4titude) or 8-well strips 
(4ti-0753/c, 4titude) and flat optical caps (4ti-0751, 4titude). All qPCR master mixes were prepared 
in a separate clean room prior to handling samples and controls. The samples were handled in a 
separate sample-handling room. The plasmid controls were applied last in a separate laminar flow 
cabinet, to minimize contamination. Pipetting to qPCR plates or strips was done in laminar flow 
cabinets sterilized with 2% Deconex and UV-light. 
3.2.1. BuV, TuV and CuV -multiplex qPCR assay 
The BuV, TuV, CuV -multiplex assay relies on the TaqMan hydrolysis probe technique (Väisänen et 
al., 2018). Probes for the three viruses were labelled with different fluorescent dyes with unique 
emission wavelenghts: FAM (~520nm) for BuV, JOE (~552nm) for CuV and Texas Red (~615nm) 
for TuV. The master mix consists of 1x Maxima probe qPCR Master Mix, without passive the 
reference dye ROX (Thermo Scientific). ROX was not used as passive reference dye, since the 
emission wavelength of ROX (~605nm) overlaps with the emission spectra of Texas Red. Maxima 
probe qPCR Master Mix is ready-to-use and contains Maxima Hot Start Taq DNA polymerase, 
dNTPs and dUTPs. Primers and probes were added to the Maxima Master Mix as follows: 0.2 µM of 
BuV and TuV probes, 0.4 µM of CuV probe, 1.0 µM of CuV forward primer and 0.5 µM of all other 
primers. Primer and probe sequences and amplicon lengths are presented in Table 1. Primers and 
probes are located in the VP2 (TuV and CuV) or NS1 (BuV) regions (Väisänen et al., 2018). 
The total volume of each reaction was 25 µL, with 5 µL of the sample template. The qPCR protocol 
was the following: hot-start at 95 °C for 10 minutes, denaturation at 95 °C for 15 seconds, annealing 
at 62 °C for 1 minute. Denaturation and annealing were repeated 45 times.  
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Table 2. Primer and hydrolysis probe sequences (‘5- ‘3) and lengths of the amplicons. The names of 
fluorophores and quenchers are marked in bold.  
 
3.2.2. Preparation of the plasmid standard  
Plasmids containing a part of BuV, TuV or CuV genomes were used as positive controls for each run 
as well as to establish the standard curve for quantification. A 3.5 kb sequence of BuV NS1 region 
(16-3577 nt, JX027295) , a 1.7 kb sequence of TuV VP2 region  (2659 - 4356 nt, KJ495710.1), and 
a 1.7 kb sequence of CuV VP2 region (2747 - 4456 nt, KT868811) had been previously cloned into 
the pSTBlue acceptor vector (Novagen) and bacterial glycerol stocks containing the plasmids had 
been stored at -70 °C. Elina Väisänen inoculated the bacteria from glycerol stocks. Isolation of a 
single colony, carrying the plasmid, was done to obtain homogenous bacterial suspension for plasmid 
purification.  
The plasmids were extracted with GeneJet Plasmid Miniprep Kit (Thermo Fischer) and the 
concentration was measured with Nanodrop 1000 Spectrophotometer (Nanodrop, Wilmington, DE) 
at 260 nm wavelength. The plasmids were verified by restriction digest. EcoRI FastDigest restriction 
enzyme (Thermo Fischer) was used for the CuV and TuV plasmids and HindIII (New England 
Biolabs) for the BuV plasmid. EcoRI cuts the CuV and TuV plasmids at two sites, resulting in two 
fragments with sizes of ~3.8 kb and ~1.7 kb. HindIII cuts the BuV plasmid at two sites, resulting in 
 
Oligo name 
 
Sequence (5’-‘3) 
 
Amplicon length 
(bp) 
BuV primer forward ACAGTGTAGACAGTGGATTCAAACTT  
 
126 
BuV primer reverse  GTTGTGGTTGGATTGTGGTTAGTTC 
BuV primer probe  FAM-CGGAAGAGATTTTGACAGTGCYTAGCAA-BHQ1 
   
CuV primer forward TAACACATCCCAGAATYGTCACATA  
118 CuV primer reverse   TTCCATTGTCTTGGAGTGCG 
CuV primer probe JOE-AGTTKTCCTGACCACCAGAAGGTTCCA-BHQ1 
TuV primer forward CCAGAAAGCCGTATCACCAT  
91 TuV primer reverse AACCAAGTGTTTCTGATCTTATTGCT 
TuV primer probe TxRd-ACACCAACAATCAACTGCCATACACACC-BHQ2 
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two fragments with sizes of 1.5 kb and 5.6 kb. All restriction digests were carried out as described in 
the manual provided by the manufacturer. Restriction digest reactions containing 1 µg of plasmid 
DNA were carried out overnight at 37 °C and the reactions were inactivated according to the product 
manuals. To visualize DNA fragments after restriction digest, 5 µL of the reaction mix was added to 
1.5 µL MidoriGreen Direct (Nippon Genetics) and applied to agarose gel electrophoresis. The 2 % 
agarose gel (SeaKem® LE Agarose, Lonza) in TAE-buffer (40 nm Tris, 20 nM Na-acetate, 3 mM 
EDTA, pH 8.0) was utilized with BIO-RAD PowerPac® power supply at 90 V for 45 minutes. The 
gel was observed under UV light (BIO-RAD Gel Doc) and stained with ethidium bromide (EtBr) for 
45 minutes.  
The plasmid copy number/µL was calculated for each control plasmid using the concentration and 
the molecular weight of the DNA. The copy number/µL of each plasmid was adjusted to 1 × 109 with 
TE-buffer (10mM Tris: 0.1mM EDTA; pH 8.0) and 10-fold dilution series was created with TE-
buffer until 1 × 100 copy/µL was reached. Furthermore, a plasmid mix was created by adding 20 µL 
of each plasmid at 1 × 109 copies/µL to 140 µL of TE-buffer. The plasmid mix was diluted into a 10-
fold dilution series using TE-buffer, until 1 × 100 copy/µL was reached (Figure 8). The performance 
of the plasmid mix dilution series was evaluated by comparing it in multiplex qPCR with single 
plasmid dilution series of CuV, TuV and BuV. Dilutions from 106 to 100 were used for each plasmid. 
In the final qPCR analyses the plasmid mix dilutions from 1 × 106 to 1 × 100 were used to create the 
standard curve. To ensure the quality of the standard plasmids, dilutions from 106 to 100 were 
aliquoted and stored at -20°C. Other plasmid preparations were stored at -70°C.  
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Figure 8. Scheme of the 10-fold dilution series of the plasmid mix. Between each dilution the mix 
was vortexed vigorously with Vortex Genie 2 (Scientific Industries Inc.) to achieve a homogenous 
mix. Picture created with BioRender (https://biorender.io/).  
 
Preliminary qPCR results were assessed with Agilent Aria 5.1. software to estimate the success of 
the run. The efficiency and the slope of the standard curve were monitored, the optimum values for 
each being ~100 and 3.4, respectively. Cq values of each replicate of the plasmid control dilution 
should vary with maximum 1 cycle.  The Agilent Aria 5.1. software calculates the viral load of each 
sample automatically based on the standard curve.  
 
3.2.3. Amplicon sequencing  
The samples that gave a positive result in qPCR for BuV, TuV or CuV were sequenced. For 
sequencing, the positive amplicons were first re-amplified by using 1 µL of the qPCR product in 4 
µL of PCR-grade water as template for singleplex qPCR. Re-amplification was done with the same 
primers and probe of the virus in question with the same master mix and qPCR program as described 
before. To check the sequences of the PCR-positive samples, the products from re-amplification were 
purified with Diffinity RapidTip® (Sigma-Aldrich) to remove primers, probes and dNTPs. The 
concentration of the purified qPCR products was measured with Nanodrop. The amplicons were 
prepared for sequencing as advised on the Institute of Molecular Medicine Finland’s (FIMM) 
websites (fimm.fi): 1.6 µL of 5 mM primer and 5.0 µL of the amplified PCR product containing 1-3 
ng of DNA. Samples were sent to FIMM for full-service sequencing in duplicates with both reverse 
and forward primers of the virus corresponding virus (Table 1.).   
3.2.4. Analysis of the sequencing results 
The sequencing results were first evaluated with SequenceScanner v1.0 software (Applied 
Biosystems) by observing the fidelity of the chromatogram. Secondly, the sequences, primers and 
templates were submitted to MultAlin software (http://multalin.toulouse.inra.fr/multalin/) to quickly 
estimate the correlation between nucleotide sequences. For each qPCR positive sample, sequences 
gained with both forward and reverse primers were aligned with the template (plasmid sequence) in 
BioEdit v7.0.5 software. The fidelity of each nucleotide was cross-checked with the chromatogram. 
The poorly-defined nucleotides or degenerative bases were fixed, when possible, based on the 
chromatogram and on the overlapping sequence gained with the other primer or according to the 
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IUPAC code. All sequences were aligned with the corresponding plasmid template to check for 
possible mismatches. Finally, all sequences were analysed with BLAST (Basic Local Alignment 
Tool, https://blast.ncbi.nlm.nih.gov/Blast.cgi) to find similarities with known sequences in the 
National Center of Biotechnology Information database.  
3.2. Developing the µ-capture IgM EIA for human protoparvovirus 
The used IgM µ-capture EIA and competition IgM µ-capture EIA protocols are based on IgM EIAs 
developed for HBoVs (Söderlund-Venermo et al.,2009 and Kantola et al., 2011). Biotinylated and 
non-biotinylated virus-like particles (VLP) were used as antigens. VP2 of BuV, TuV and CuV can 
self-assembe into virus-like particles (Ilyas et al., 2018; Väisänen et al., 2016, 2018).  
3.2.1. Optimizing the BuV1 µ-capture IgM EIA 
Before screening the Iran serum sample cohort with the BuV1 µ-capture IgM EIA, several factors 
were studied to optimize the assay. First step of optimizing the assay was to test different 
concentrations of the biotinylated BuV1 VLP antigen. From the Iran cohort, 18 randomly selected 
serum samples were analyzed with IgM µ-capture EIA using three different antigen concentrations: 
10 ng, 20 ng and 40 ng per 100 µL. The chosen antigen concentrations were based on what had 
previously been used for other parvoviruses in IgG or IgM (Chen et al., 2011; Söderlund-Venermo 
et al., 2009; Kantola et al., 2011; Riipinen et al., 2010; Väisänen et al., 2018; Väisänen et al., 2016; 
Maple et al., 2014). Two diluents were compared for the serum dilutions: RED buffer solution 
(Kaivogen) and Phosphate buffered saline solution (PBS), using 16 randomly selected samples in the 
Iran cohort. Two different substrate incubation times were tested: 15 min and 20 min.  
Based on antigen concentration, serum diluent and substrate incubation testing experiments, the 
protocol described below was chosen. 
3.2.1. BuV1 µ-capture IgM EIA  
Costar E.I.A/R.I.A strips were coated with goat antiserum to human IgM (Cappel, MP Biomedicals) 
with a dilution of 1:1200 in 0.05 M carbonate buffer (bicarbonate buffer capsules, Sigma), pH 9.6. 
The coating was done at room temperature (RT) (+24 °C) by adding 100 µL of the antiserum dilution 
to each well. The strips were incubated overnight at RT. After incubation, 100 µL of 3 % bovine 
serum albumin (BSA) (Sigma-Aldrich) in phosphate-buffered saline (PBS) was pipetted into each 
well. Strips were incubated for 30 minutes at +37°C. After incubation, wells were washed with PBS 
and 0.05 % Tween 20 (PBST) buffer. Finally, the dried strips were stored at -20 °C until use.  
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The serum samples were diluted 1:200 into RED buffer solution (Kaivogen) and each sample was 
applied to pre-coated wells in duplicates, 100 µL per well. Serum dilutions were incubated for 60 
minutes at RT with 400 rpm shaking. Wells were rinsed five times with 300 µL of PBST. Biotinylated 
BuV1 VP2-VLP antigen was diluted into PBST with 0.5 % BSA to the desired concentration of 10 
ng, 20 ng or 40 ng per 100 µL. The diluted antigen was applied to the wells, 100 µL into each, and 
the mixture was incubated for 45 minutes at +37 °C without shaking. After antigen incubation, wells 
were washed as described before. Peroxidase-conjugated streptavidin (Dako) was diluted 1:12000 
into PBST with 0.05 % BSA, 100 µL of the dilution was distributed into each well. Strips were 
incubated and washed as described in the previous step. After the conjugate incubation, 100 µL of 
3,3′,5,5′-Tetramethylbenzidine (TMB) substrate (Sigma) was dispensed to each well. Substrate was 
incubated for 15 or 20 minutes at +37 °C. To stop the reaction, 100 µL of 0.5 M sulfuric acid H2SO 
(Fluka) was added to each well. Absorbance was measured with a wavelength of 450 nm (Multiskan 
EX, Thermo Labsystems). A strip with 100 µL of TMB substrate and 100 µL of sulfuric acid was 
used as a blank. The blank value was subtracted from the test results. No BuV1-IgM positive or 
negative serum sample was available to be used as a control. Instead, well-characterized B19V-IgM 
positive and negative serum samples were used as technique and reagent controls for each assay in 
B19V VP2 µ-capture IgM EIA (Maple et al., 2014). 
3.2.2. BuV1-3 and CuV µ-capture competition IgM EIA  
To verify the specific IgM to BuV1 antigen and to rule out possible cross-reactivity to BuV2-3 and 
CuV antigens, µ-capture competition IgM EIA was performed in a set of serum samples that were 
considered putatively positive in BuV1 µ-capture IgM EIA. A total of six serum samples were tested 
with competition EIA for all BuVs (1-3) and CuV. Each serum was assigned to homologous and 
heterologous competition with three VLPs and one well was assigned to no competition treatment. 
Two non-biotinylated antigen concentrations, 20 µg and 30 µg per well, were tested in two separate 
µ-capture competition IgM EIAs. 
The antiserum-coating of the wells, serum incubation and the first wash were done as described for 
the BuV1 µ-capture IgM EIA. To maximize the binding of the non-biotinylated antigen, a pre-
incubation was done with 100 µL PBST containing 0.5 % BSA or with 100 µL of the non-biotinylated 
antigen (20 µg or 30 µg per ml) diluted into PBST with 0.5 % BSA. The pre-incubation was done at 
+4 °C for 1.5 hours. After the pre-incubation, the mixtures were removed by suction. Next, 100 µL 
of the biotinylated VLPs (20 ng per well) or a mixture of biotinylated VLPs (20 ng per well) and non-
biotinylated homo- or heterologous VLPs (20 µg or 30 µg per ml) were applied to the wells. The 
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mixtures were incubated for 45 minutes at +37 °C. Washing, substrate incubation, termination of the 
reaction, blank strip preparation and the absorbance measurement was conducted as described for 
BuV1 IgM µ-capture EIA.  
If the sample has IgM antibodies for a specific antigen the signal is blocked after incubation with 
homologous non-biotinylated antigen, whereas incubation with heterologous non-biotinylated 
antigens should not block the specific reaction. The absorbance value measured in the no competition 
well should correspond to the µ-capture IgM EIA result.  
 
3.2.3. Troubleshooting the µ-capture IgM EIA 
To troubleshoot the µ-capture IgM EIA, different variables of the assay were studied. It was 
investigated whether storage of the pre-coated strips affect the IgM binding performance of the goat 
antiserum to human IgM. Strips after 1 year, 3 months, 10 days and 1 day of storage were compared. 
The performance of streptavidin used in all the assays was compared with a fresh streptavidin. The 
strips and streptavidin conjugate were tested using the well-characterized B19-IgM positive and 
negative serum samples, which were used as technique and reagent controls in BuV1 µ-capture IgM 
EIA, as well as Sample N30 from the Iran serum sample cohort. The B19-positive and negative 
samples were tested with B19 VP2 µ-capture IgM, with antigen concentration of 10 ng/well. The 
sample N30 was tested with the BuV1 µ-capture IgM EIA, with antigen concentration of 10 ng/well. 
Finally, the used VLPs were examined by producing new biotinylated and non-biotinylated VLPs 
and comparing the performances of the different VLP batches in IgM and IgG.   
3.2.4. Production and purification of CuV VP2 VLPs  
VLPs were produced as the final attempt to troubleshoot the IgM EIA. Instead of producing BuV1 
VLPs, CuV VP2 VLPs were chosen due to the incoherent results with CuV VLPs in IgM competition 
EIA.  
For CuV VP2 VLP production, High five insect cells were thawed from liquid nitrogen storage and 
suspended into Xpress insect cell media (Lonza Biosciences) with 10 % fetal bovine serum (FBS) 
(Gibco). The cells were let to attach to the T25 flask bottom for one hour after which the media was 
changed to new, in order to remove any residual of dimethyl sulfoxide (DMSO) present in the storage 
media. The cells were grown in T25 flasks (Sigma-Aldrich) at +27 °C. Cells were passaged every 2 
to 4 days and were transferred during the first passages from the T25 flask to a T75 (Sigma-Aldrich) 
flask and finally to a T175 (Sigma-Aldrich) flask. Amphotericin B, penicillin and streptomycin were 
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gradually added during the first passages. The amount of antibiotics was increased by 20 % in during 
each passage, until the final concentrations of 25 µg/ml of amphotericin B, 100 U/ml of penicillin 
and 100 µg/ml of streptomycin were reached. When the growth of the culture reached a stable state 
and the cells were adjusted to the final concentration of antibiotics, the cells were split into 1:10 
creating several parallel cultures in T175 flasks.  
Before infection the cells were split to 1:7 and incubated overnight. The insect cells were infected 
with 500 µL of passage 3 media of recombinant baculovirus, containing the CuV VP2 gene (Väisänen 
et al., 2018). The infected cells were cultivated in a separate infection room at +27 °C. The culture 
was followed every day and on average 4-6 days post infection, the cells were visibly dead i.e. 
detached from the bottom of the flask. On average, 24-30 T175 flasks were infected simultaneously. 
The detached cells were collected by centrifuging for 5 minutes at 4000 rpm (Heraeus, Megafuge 10). 
The cell pellet was resuspended into approximately 30 ml of 20 mM Tris-HCl with 2x EDTA-free 
protease-inhibitor (Roche) with 0.5 % deoxycholic acid (DOC) (Sigma-Aldrich). The mixture was 
distributed into 15 ml Falcon tubes and incubated at +37 °C with mild shaking for 30 min and chilled 
on ice for 15 minutes. Cells were sonicated with an ultrasonic probe sonicator (Bandelin, Sonoplus) 
with the following program: 10 s agitation + 10 s pause for eight times with 50% amplitude. During 
sonication the cell tube was immersed in an ice bath to prevent heating. After sonication the cells 
were centrifuged with full speed (Eppendorf Centrifuge 5415 R) for 30 minutes at +4 °C. The 
supernatant was collected, and the pellet was resuspended into 20 mM HCl-Tris with 2x EDTA-free 
protease -inhibitor. Sonication and centrifugation were repeated.  
The VLPs were purified by caesium chloride (CsCl) ultracentrifugation. A double cushion of CsCl 
was created by preparing a CsCl Solution 1 with a density of 1.52 g/cm3 (heavy). The CsCl powder 
was dissolved into TE-buffer. Solution 2 was created diluting Solution 1 with TE-buffer with a ratio 
of 57:43 resulting in a final density of 0.653 g/cm3. A double cushion was created into each 
ultracentrifuge tube (Beckman&Coulter) by carefully pipetting in the following order from bottom to 
top: 7 ml of Solution 1, 11 ml of Solution 2, ~15 ml of cell lysate and, if needed, the tube was filled 
to the top with TE. Depending on the growth of the cells, pellets from 4-7 cells flasks were pipetted 
to each centrifuge tube. The lysates were then centrifuged for 16 hours, 26 000 rpm, +10 °C (Beckman 
L-70). 
During ultracentrifugation VLPs formed a visible band, which was collected to microtubes. 
Approximately 4-6 ml of VLPs were collected from each ultracentrifuge tube. To ensure maximum 
purity, the ultracentrifugation was repeated. Between ultracentrifuge purifications, VLPs were 
dialysed against PBS for 6 hours to remove CsCl. The final purified product was further dialysed 
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against PBS for 18 to 24 hours changing PBS every 6 to 8 hours. The dialyses were done at +4 °C 
with constant mixing. After ultracentrifugation VLPs were analysed on sodium dodecyl sulphate–
polyacrylamide gel electrophoresis (SDS-PAGE) (10% acrylamide/bis) at 90 V for 1.5, hours with 
Precision Plus Protein™ Dual Colour Standard as standard. If needed, the VLPs were concentrated 
with Amicon Ultra Centrifugal Filter Units. Concentration of the VLPs was measured with Pierce 
BCA Protein Assay Kit (Thermo Fischer). Biotinylation of the VLPs was done with EZ-Link® Sulfo-
NHS-LC-Biotin (Thermo Fischer) with 20-fold molar excess of 10 mM biotin according to the 
manufacturer’s instructions.  The unbound biotin was removed by dialysis. The biotinylated VLPs 
were stored at -20 °C in PBS with 0.5 % sodium azide (NaN3), 4 mg/ml BSA, 50 % glycerol and 4 
% EDTA -free protease inhibitor (Roche) in PBS. The non-biotinylated VLPs were stored at +4 °C 
with 0.5 % NaN3.  
The performance of the biotinylated and non-biotinylated CuV VP2 VLPs were tested in non-
competition and competition IgG EIA (Väisänen et al.,2016) using a known BuV1-3 -positive serum 
sample with CuV cross -reactivity and known CuV -positive and -negative serum samples. Briefly, 
80 ng/well and 160 ng/well of the biotinylated CuV VLPs were diluted in PBST and applied to 
streptavidin-coated plates (UniverSA96-Lockwell, Kaivogen). The plate was incubated for 1 hour at 
RT with 400 rpm shaking. Plates were post-coated with the Diluent (Labsystems Diagnostics) 3 times 
for 10 minutes 150 µL/well. The serum samples were diluted 1:200 in RED buffer and incubated for 
1 hour at RT with 400 rpm shaking. The wells were washed with 300 µL of PBST 4 times within 15 
minutes. A secondary-antibody HRP-conjugated anti-human IgG (DAKO, #P124) was diluted 1:4000 
in the Diluent and applied 100 µL per well. The secondary conjugated -antibody was incubated for 1 
hour at RT with 400 rpm shaking. Wells were washed with PBST as previously. TMB was used as 
substrate and the reaction was stopped with H2SO. For the competition assay the serum samples were 
pre-incubated with non-biotinylated antigen for 1.5 h at +4 °C, using CuV and BuV2 VLPs. Results 
were measured as described for IgM EIA.  
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4.  RESULTS 
The aims of this thesis were to screen three patient cohorts for BuV, TuV and CuV DNA with in-
house multiplex qPCR and to develop an IgM EIA for human protoparvoviruses using BuV1 as an 
example.  
4.1.Multiplex qPCR 
4.1.1. The plasmid standard 
To verify that all the extracted plasmids were holding the correct insert, restriction analyses were 
done in duplicate reactions (A and B) for each plasmid. The plasmid containing a part of the BuV 
genome was digested with HindIII restriction enzyme. HindIII cuts the BuV plasmid at two sites 
resulting in fragments with expected sizes of ~1.5 kb (part of the insert) and ~5.6 kb (part of the insert 
+ vector backbone). The plasmids containing a part of the CuV or TuV genome were digested with 
EcoRI restriction enzyme, which cuts both plasmids into two fragments: ~1.7 kb (insert) and ~3.8 kb 
(plasmid backbone). Analysis of the digested plasmids by agarose gel electrophoresis are presented 
in Figure 9. Plasmids BuV A and B, TuV A and B and CuV A were cut as expected and resulted in 
correct sized fragments. Fragments for the digested plasmid CuV B were observed to be shorter than 
expected. It was evaluated that CuV B plasmid was not cut correctly and it was not used for the 
plasmid standard dilutions.   
Plasmids BuV B, TuV A and CuV A were chosen for the plasmid standard dilutions. Concentrations 
of the plasmids were measured with Nanodrop: 378 ng/µL for the BuV plasmid, 198 ng/µL for the 
TuV plasmid and 168 ng/µL for the CuV plasmid.  
 
Figure 9. Analysis of restricted plasmids BuV, TuV and CuV by agarose gel electrophoresis. From 
left to right: restricted BuV plasmids A and B, restricted TuV plasmids A and B and restricted CuV 
plasmids A and B. For BuV the fragment sizes were as expected: ~5.6 kb and ~1.5 kb. TuV A and B 
as well as CuV A plasmid restrictions had correct sizes after the restriction analysis: ~1.7 kb and ~3.8 
kb. The used size standards are on the right side of the picture: Generuler ladders 100 bp (ST100) and 
1 kb (ST1000) (Fermentas). Sizes for the 1 kb ladder are presented on the right side of the ladder.  
3000 bp 
250 bp 
1000 bp 
1500 bp 
2000 bp 
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Each plasmid was diluted in a 10-fold dilution series from 1 × 109 to 100 copies/µL. In addition to 
that, a plasmid mix was created by combining the 1 × 108 copies/µL dilution of each plasmid. The 
mix was further on diluted as a 10-fold dilution series until 1 × 100 copy/µL was reached. The aim 
was to use the plasmid mix to create the quantification standard for the qPCR. Before sample analysis, 
the performance of the plasmid mix was compared with the single plasmid dilutions to ensure correct 
quantification. For this, all single plasmid and the plasmid mix dilutions from 1 × 100 to 106 copies/µL 
were analyzed with the BuV, TuV, and CuV –multiplex qPCR in a single qPCR assay. The Cq values 
from each individual plasmid dilutions were compared to each other as well as to the Cq values of the 
plasmid mix. As is visualized in Table 3, all single plasmid and plasmid mix dilutions have similar 
Cq values when compared to each other. Based on this assay, the plasmid mix dilutions from 1 × 10
0 
to 106 copies/µL were used to create the quantification standard for the sample analysis. Mean Cq 
values and standard deviations are calculated from two replicates of each dilution.  
 
Table 3. DNA quantification from single plasmid dilutions and the plasmid mix dilutions from 1 × 
100 to 106 copies/µL. Mean Cq values and standard deviations were calculated from two replicates 
of each dilution. 
 
4.1.1. All three viruses were identified in the stool sample cohorts 
A total of 407 stool samples from Malawi, HUSLAB b and v cohorts were screened with BuV, TuV 
and CuV multiplex qPCR. All samples were analyzed as duplicates, except for the HUSLAB v cohort, 
for which there was enough sample for only one qPCR reaction. The qPCR analyses included a total 
of 170 negative controls, PCR-grade water, all of which were negative. The screening of the Malawi, 
HUSLAB v and b cohorts revealed a total of 2/407 samples positive for BuV DNA (0.5 %), 2/407 
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samples positive for TuV DNA (0.5 %) and 13/407 samples positive for CuV DNA (3.2 %). Summary 
of all qPCR screened fecal DNA preps is presented in Table 4.  
 
Table 4. Summary of all the BuV, TuV, CuV qPCR -positive samples grouped by the detected virus 
and cohort. 
 
BuV DNA was found in one stool sample in the HUSLAB b cohort (1/172, 0.6%) and in one stool 
sample in the Malawi cohort (1/179, 0.6%). Both samples were BuV DNA qPCR-positive in two out 
of two replicates. The viral load range of the stool samples was 1.5 ×104 - 1.2 × 103 copies/ml (Figure 
10), average 7.9 × 103 copies/ml. The BuV DNA-positive stool sample in the HUSLAB b cohort has 
been previously identified as BuV DNA-positive and has been published in Väisänen et al., 2014. 
This sample was not sequenced and is not included in the analyses. QPCR analysed initially gave a 
positive signal for TuV DNA in two stool samples. Both of the TuV DNA-positive samples belonged 
to the HUSLAB b cohort (2/172, 1.2%) and were positive only in one of the two replicates.  The DNA 
quantities in the stool samples were 3.9 × 102 and 1.0 × 102 copies/ml (Figure 10). A total of  13 stool 
samples were CuV DNA-positive of which, one was from the HUSLAB b cohort (1/172, 0.6%), three 
were from the HUSLAB v cohort (3/56, 5.4%) and nine were from the Malawi cohort (9/179, 5.0%). 
From the 13 CuV DNA-positive stool samples five were positive in two out of two replicates and 
eight were positive for CuV DNA in one out of two replicates. The viral loads of the samples varied 
from 4.1 ×104 to 3.8 ×102 copies/ml (Figure 10), median 8.5 ×103 copies/ml.  
 
All stool samples positive for TuV and CuV DNA in qPCR were sequenced as well as the BuV DNA 
qPCR-positive stool sample from the Malawi cohort. 
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Figure 10. Viral loads detected in the fecal DNA preps from all the cohorts grouped by the detected 
virus. On the y-axis are copies/µL in log10. For each sample, an average viral load was calculated 
from the positive replicates. On the x-axis are all qPCR-positive samples grouped by the detected 
virus. Two samples that gave a positive result in the qPCR are marked with red (one TuV and one 
CuV DNA positive), see chapter 4.1.2.  
 
4.1.2. Sequencing results  
All samples, which gave a positive signal for BuV, TuV or BuV in the multiplex qPCR were 
sequenced with both forward (fwd) and reverse (rev) primers of the detected virus. Sample 2 in the 
Malawi stool sample cohort gave a qPCR-positive signal for BuV DNA (1/407) in both replicates. 
Sequencing yielded good quality data with both primers with lengths of 88 (fwd) and 89 (rev) bases 
(Figure 13). Two mismatches can be detected when compared to BuV-1 strain BF.7 (plasmid target 
sequence), from 5’ to 3’ G=A and G=A (Figure 11). BLAST analysis revealed that Sample 2-derived 
amplicon sequence had a 99 % identity with BuV-1 isolate H232 (KU362761.1), BuV-3 strain 
BJ2180/BeiJing/2014 (KM580355.1), BuV-3 strain BJ189/BeiJing/2011 (KM580352.1) and BuV-2 
strain BF.39 (JX027297.1). The BLAST analysis was conducted with standard parameters.  
 
A total of 2/407 samples gave positive signals for TuV DNA in multiplex qPCR, 13FV73 and 13FV10 
in the HUSLAB b cohort. Both samples were positive in only one replicate in qPCR and were 
sequenced. For Samples 13FV73 and 13FV10 the gained sequences, with fwd and rev primers, were 
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135 bp, 134 bp, 302 bp and 293 bp, respectively. The TuV amplicon length is 118 bp. Sequences 
from the Sample 13FV73 –derived amplicon were approximately 20 nucleotides longer than the 
expected TuV amplicon and had 6 mismatches when compared to the plasmid target sequence (TuV1 
Tu491) (Figure 11). The sequenced amplicon from Sample 13FV73 was analyzed with BLAST and 
had a 95 % sequence identity with TuV sp. isolate T.2VLP (KX856940.1) and TuV1 strain Tu491 
(KJ495710.1). Sequence data obtained from the Sample 13FV10 –derived amplicon was of bad 
quality and the gained sequences did not match the expected amplicon in length nor did the sequences 
match the TuV plasmid target sequence. From the sequence gained with the TuV fwd primer, perfect 
matches for TuV rev and CuV rev primers sequences were found and from the sequence gained with 
the TuV rev primer, TuV fwd sequence were identified. Both Sample 13FV10 –derived amplicon 
sequences with rev and fwd primers were analyzed by BLAST with standard parameters and the 
sequences share, respectively, an identity of 84 % and 86 % with Alistipes shahii WAL 8301 draft 
genome (FP929032.1). Alistipes is a genus in phylum Bacteroides, an anaerobic bacteria that can 
inhabit the human gut (Song et al., 2006). Therefore, sample was not considered positive for TuV 
DNA. A total of 0.25 % of all analysed samples were positive for TuV DNA.  
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Figure 11.  Alignment of all the sequenced qPCR-amplicons from BuV, TuV or CuV DNA-positive 
stool samples. A. BuV sequences from top to bottom: BuV2 BF. 39 (JX027297.1) (the plasmid target 
sequence), BuV1 strain BF.96 (JQ918261.1), BuV isolate H232 (KU362761.1), BuV3 strain 
BJ2180/BeiJing/2014 (KM580355.1), BuV3 strain BJ189/BeiJing/2011 (KM580352.1), BuV2 strain 
BF.39 (JX027297.1) and Sample 2 (Malawi cohort). B. TuV sequences from top to bottom: TuV1 
Tu491 (KJ495710.1) (plasmid standard target sequence), TuV sp. T.2VLP (KX856940.1) and Sample 
13FV73 from the HUSLAB b cohort. C. CuV sequences from top to bottom: CuV BR-337 
(NC_039050.1) (the plasmid target sequence), CuV CGG5-268 (KX685945.1), CuV BR-372 
(KT868809.1), CuV FR-F (KT868815.1), Samples 29, 36, 37, 68, 76, 129, 146, and 181 from the 
Malawi cohort, Samples 2261, 2291 and 2299 from the HUSLAB v cohort and Sample 13FV38 from 
the HUSLAB b cohort. All sequences are presented as ‘5 to 3’, sequences aligned with BioEdit v7.0.5 
software. Dot (.) indicates identical nucleotides, a line (-) indicates an unidentified nucleotide. 
C. 
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A total of 13/407 samples gave a positive signal for CuV DNA in the multiplex qPCR. Samples 68, 
76, 129 and 146 in the Malawi cohort and the Samples 2299 and 13FV38 in the HUSLAB v and b 
cohorts gave positive signals in both qPCR replicates. Samples 29, 36, 37, 54 and 181 in the Malawi 
and Samples 2261 and 2292 in the HUSLAB v cohort were positive in only one qPCR replicate. 
Sequencing yielded relatively good quality data for all the sequenced amplicons, except for the 
amplicon derived from Sample 54 in the Malawi cohort. The CuV amplicon is only 91 bps long, so 
sequences gained with fwd and rev primers had only little overlap. For samples 37, 76, 2261, 2292, 
2299 and 13FV38 the overlapping part was so short that it resulted in a gap in the middle of the 
analyzed sequences. All samples have a few mismatches when compared to the CuV target sequence 
(CuV BR-337) (Figure 11.). Samples 29, 36, 37, 68, 76, 129, 146 and 181 in the Malawi cohort and 
Samples 2261, 2292, 2299 and 13FV38 in the HUSLAB v and b cohorts, respectively, were identified 
positive for CuV DNA. For Sample 54 the obtained sequences were 154 (fwd) and 153 (rev) bases in 
length, which is not correct for the CuV target amplicon. Furthermore, the sequences did not match 
the CuV plasmid target sequence. A near-perfect match for BuV fwd and BuV rev primer sequences 
can be found from the sequences gained with the CuV rev and CuV fwd primers, respectively. Both 
sequences were analyzed by BLAST. The sequence acquired with the rev primer gave no results, 
whereas Sample 54 derived amplicon sequence with fwd primer shared a sequence identity of 95 % 
with the BuV isolate H232 (KU362761.1), BuV3 strain BJ2180/BeiJing/2014 (KM580355.1), BuV3 
strain BJ189/BeiJing/2011 (KM580352.1) and BuV2 strain BF.39 (JX027297.1), which indicates that 
Sample 54 in the Malawi cohort is not positive for CuV, but in fact for BuV DNA.  
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4.2.The µ-capture IgM EIA  
4.2.1. Optimizing the BuV1 µ-capture IgM EIA  
Before screening the Iran serum sample cohort with BuV1 µ-capture IgM EIA, three different 
concentrations, 10, 20, and 40 ng per well, of the biotinylated BuV1 VLP antigen were tested with 
18 randomly selected serum samples in the Iran cohort (Figure 12). For the 10 ng per well 
concentration BuV1 IgM absorbance values varied from 0.054 to 0.181, median 0.095. Absorbance 
values with the 20 ng per well concentration varied from 0.101 to 0.309, median 0.160 and with the 
40 ng per well concentration from 0.185 to 0.605, median 0.309. The calculated cutoff absorbance 
value for a putatively positive sample in the HBoV1 µ-capture IgM EIA is 0.131 (Kantola et al., 
2015) and 0.100 in the BuV1-3 and CuV IgG EIA (Väisänen et al., 2016). Based on these cutoff 
values, it was evaluated that the 40 ng per well antigen concentration gave excessively high 
absorbance values. It was decided that BuV1 VLP antigen concentrations of 10 and 20 ng per well 
will be used to screen the whole Iran serum sample cohort. In addition, the substrate incubation time 
was lowered to 15 minutes.  
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Figure 12. BuV1 µ-capture IgM EIA using 18 randomly selected serum samples from the Iran cohort 
analyzed with three different concentrations of biotinylated BuV1 antigen: 10, 20 and 40 ng per well. 
The absorbance values are grouped based on the used antigen concentration. Median absorbance 
values are marked with thick black line and the standard deviations with thin black lines. Substrate 
incubation time was 20 minutes.  
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Properties of PBST and RED buffer solution as diluents were compared with 16 serum samples in 
the Iran cohort and with two BuV1 VLP antigen concentrations: 10 ng and 20 ng per well. Median 
absorbance values for samples diluted in PBST were 0.106 and 0.158, with BuV1 VLP concentrations 
of 10 ng and 20 ng per well, respectively. Median absorbance values were very similar when diluted 
in RED buffer: 0.101 with BuV1 VLP concentration of 10 ng/well and 0.161 with 20 ng/well 
concentration.  Results are presented in Figure 13. RED buffer was used as the diluent for screening 
the Iran serum sample cohort with BuV1 µ-capture IgM EIA.  
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Figure 13. Two serum diluents, phosphate buffered saline solution with 0.05 % Tween 20 and RED 
buffer solution (Kaivogen), were compared in BuV1 µ-capture IgM EIA using two biotinylated BuV1 
antigen concentrations: 10 ng and 20 ng/well. A total of 16 randomly selected serum samples in the 
Iran cohort were used for the assay. Substrate incubation time was 15 minutes. Absorbance values 
are grouped by diluent and the used antigen concentration. Results are presented with median (thick 
black line) and standard deviation (thin black line).  
 
4.2.2. Screening the Iran serum sample cohort with the BuV1 µ-capture IgM EIA 
A total of 118 serum samples in the Iran cohort were analyzed with two concentrations of biotinylated 
BuV1 VLP antigens (10 ng and 20 ng per well) in the BuV1 µ-capture IgM EIA. With 10 ng of the 
biotinylated antigen in the well, the absorbance values varied from 0.034 to 0.744, median 0.126 and 
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with 20 ng per well concentration absorbance values fluctuated from 0.081 to 1.08, median 0.205. 
Results are presented in Figure 14. Samples N27 and N67 gave significantly high absorbance values 
in µ-capture IgM EIA, 0.744 and 0.518 with 10 ng per well concentration and 1.08 and 1.05 with 20 
ng per well concentration, respectively. Also, Samples N18, N43, N44 and N101 gave relatively high 
absorbance values in the µ-capture IgM EIA with the 20 ng/well antigen concentration: 0.328, 0.463, 
0.394 and 0.525, respectively. Samples N27, N67, N18, N43, N44 and N101 were considered 
putatively BuV1 IgM positive and were included in the competition IgM EIA panel. The well-
characterized B19V-IgM positive and negative serum samples, used as technique and reagent controls 
for each assay, gave expected results in the B19V VP2 µ-capture IgM EIA. 
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Figure 14.  Samples in the Iran cohort (n=188) analyzed with BuV1 IgM µ-capture EIA with two 
antigen concentrations: 10 ng or 20 ng per well. Results are grouped by the antigen concentration and 
presented with the median absorbance value (thick black line) and standard deviation (thin black line).  
 
With the 20 ng per well concentration of the biotinylated BuV1 VLPs, 40 samples gave absorbance 
values over 0.220. DNA was extracted from the 40 serum samples and analyzed with the Buv, TuV, 
CuV multiplex qPCR to detect possible viremia and to verify the BuV1 µ-capture IgM EIA results. 
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4.2.3. Results for the competition BuV1-3 and CuV µ-capture IgM EIA were ambiguous  
In order to evaluate the specificity of the VLP based IgM µ-capture EIA, two competition assays 
were done with six serum samples in the Iran cohort (N18, N27, N43, N44, N67 and N101). Each 
serum sample was subjected to no competition (corresponding to µ-capture IgM EIA) as well as to 
homologous and heterologous competition with BuV1-3 and CuV. Two concentrations were tested 
for the non-biotinylated (blocking) antigens in separate assays: 20 µg per ml in the first assay and 30 
µg per ml in the second assay. All results are presented in Figure 15. The exhaustive competition and 
pre-incubation with homologous non-biotinylated antigen should block the binding sites from the 
common epitopes of the biotinylated VLP antigen, giving minimal residual absorbance values. The 
absorbance values in a single serum sample treated with no competition should be comparable 
between assays including the IgM µ-capture EIA results.  
Based on the competition µ-capture IgM EIAs all six serum samples were interpreted as negative for 
BuV2 IgM antibodies, each sample gave absorbance value below 0.09. For the other analysed VLPs, 
the competition assays did not perform as expected. The absorbance values for single sample with no 
competition treatment in BuV3 or CuV competition IgM µ-capture EIA were not comparable when 
the assays were repeated (Figure 15). Moreover, in the case of the BuV1 EIAs, the absorbance values 
for individual sample were comparable neither in the no competition treatment in the competition 
IgM µ-capture EIAs nor in the µ-capture EIA (Table 5, Figure 15.). For example, Sample N67 gave 
absorbance values of 1.051 and 0.518 in the BuV1 µ-capture IgM EIA with 10 ng and 20 ng 
biotinylated VLPs per well, respectively. However, the absorbance levels were 0.271 and 0.328 with 
no competition treatment in the BuV1 competition µ-capture IgM EIA. Similar incoherence in 
absorbance values can be detected also for the other five serum samples (N18, N27, N43, N44 and 
N101) when measured for BuV1 VLP antibodies. In the case of CuV µ-capture IgM EIA competition 
panels, the absorbance values were blocked neither by the homologous nor the heterologous 
competition in most cases, indicating non-specific reactivity. For example, Sample N18 gave 
absorbance values of 0.603 with no competition, 0.534 with homologous competition and 0.493 with 
heterologous competition (30 µg well of each non-biotinylated antigen). Based on these results, 
several components of the µ-capture IgM EIA were studied to track down the reason behind the 
incoherent and non-specific results.  
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Table 5. Examples of absorbance values in the BuV1 µ-capture IgM EIA and in the in the no 
competition treatment in the competition BuV1 µ-capture IgM EIA. Assay A: The BuV1 µ-capture 
IgM EIA for all samples in the Iran serum sample cohort, with two BuV1 antigen concentrations: 10 
ng and 20 ng/well, B. The no competition treatment in the competition BuV1 µ-capture IgM EIA C. 
The no competition treatment in the second competition BuV1 µ-capture IgM. The absorbance values 
from the no competition treated wells in the competition µ-capture IgM EIA should be comparable 
with the results in BuV1 µ-capture IgM EIA. 
Biotinylated 
antigen in the well 
BuV1 10 ng/well BuV1 20 ng/well 
Sample ID Absorbance value (450 nm) 
Type of assay A.  B. C. A. 
N27 0.744 0.244 0.110 1.080 
N43 0.299 0.244 0.134 0.463 
N44 0.271 0.576 0.129 0.394 
N67 0.518 0.271 0.328 1.051 
N18 0.188 0.366 0.112 0.328 
N101 0.335 0.147 0.123 0.525 
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Figure 15. Six serum samples in the Iran cohort analyzed with the BuV1-3 and CuV competition µ-
capture IgM EIAs. From top left to the bottom right: BuV1, BuV2, BuV3 and CuV IgM EIA, with 
no competition (circle with no fill), homologous competition (circle with fill) and heterologous 
competition (triangle). Symbols marked with black represent the competition assay done with 20 
µg/ml of non-biotinylated antigen and symbols marked with red the assay with 30 µg/ml non-
biotinylated antigen.  
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4.2.4. BuV, TuV or CuV DNA was not found in the selected 40 serum samples in the Iran cohort by 
multiplex qPCR 
All serum samples in the Iran cohort, which gave an absorbance value of 0.220 or higher in the BuV1 
µ-capture IgM EIA (n=40), were analyzed with the BuV, TuV, CuV multiplex qPCR, to study 
possible viremia and verify the EIA results. The DNA from the serum samples was extracted with 
the phenol-chloroform extraction method. Replicates of each sample were analyzed in separate qPCR 
assays with 10 extraction controls and 6 negative controls in each. In the first multiplex qPCR assay 
5 out of 40 samples were positive for CuV DNA and none for BuV or TuV DNA. In the second assay 
3 out of the 40 analyzed samples were positive for CuV DNA and none for BuV or TuV DNA. In 
addition, one extraction control was positive for CuV DNA. Only one sample was positive in both 
qPCR runs. All samples, and the extraction control, which gave a positive result in the multiplex 
qPCR were analyzed in replicates with CuV singleplex qPCR with 6 negative controls. None were 
positive. All serum samples were considered negative for BuV, CuV and TuV DNA, which indicates 
that the putatively positive results in the BuV1 µ-capture IgM EIAs, were false positives.  
 
4.2.5.  Troubleshooting the µ-capture IgM EIA 
Due to the incoherent results in the competition µ-capture IgM EIA (Figure 15, Table 5.), the assay 
and assay performance was investigated. All laboratory notes were revised, to detect any mistake in 
calculations or in execution of the assays. Nothing that could explain the results was found. Next, the 
antiserum-coated strips stored for 1 day, 10 days, 3 months and 1 year and a new and old aliquot of 
the streptavidin conjugate were studied. The strips and the streptavidin conjugate were tested with 
the B19V µ-capture IgM EIA (Maple et al., 2014) using well-characterized B19V-IgM positive and 
negative serum samples and with BuV1 µ-capture IgM EIA using the Sample N30 from the Iran 
serum sample cohort. There was no significant difference in absorbance values regardless of whether 
the sample was treated with the old or the new aliquot of streptavidin conjugate or which strip was 
used (Figure 16.). For example, the absorbance values for the known B19V IgM-positive serum 
varied in B19V IgM EIA from 2.22 to 1.93 with different antiserum-coated strips (the cutoff values 
for B19V borderline and -IgM positivity is 0.171-0.220, respectively). The well-characterized B19V-
IgM negative serum sample was negative in all the tests, the median absorbance values varied from 
0.03 to 0.02 (the cutoff value for a negative B19 IgM is < 0.171). Absorbance values for Sample N30 
varied from 0.09 to 0.06 with the BuV1 µ-capture IgM EIA and was considered negative based on 
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these tests. It was evaluated that neither the strips nor the used streptavidin conjugate was the reason 
behind the incoherent results in the competition µ-capture IgM EIA. 
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Figure 16. Testing the antiserum-coated strips after 1 day, 10 days, 3 months and 1 year of storage 
as well as a new and old aliquot of the streptavidin conjugate. The results are grouped on the x-axis 
by the used streptavidin aliquot. The colors of the dots represent the storage time of the strips:  1 day 
(red), 10 days (green), 3 months (blue) and 1year (black). Absorbance value measured at 450 nm is 
on the y-axis.  
 
4.2.6. The CuV VLP production and testing of the new VLPs in CuV IgG and IgM EIA 
In orded to study whether the purity, storage or the used VLP batch effected the performance of the 
µ-capture IgM EIA, new CuV VLPs were produced. CuV VLPs were chosen to be produced due to 
the incoherent results in the competition CuV µ-capture IgM EIAs and our stock were becoming 
scarce. The prepared batches of biotinylated and non-biotinylated CuV VLPs were purified two times 
by ultracentrifugation to remove all possible impurities. The correct size of the produced CuV VLPs 
was verified by SDS-PAGE (Figure 17.). The correct size for the CuV VP2 VLP is ~65 kilodaltons 
(kDa) (Väisänen et al., 2018).  The CuV VLP production was successful and yielded two batches, 
which were tested in CuV IgG EIA (Väisänen et al., 2016) and in CuV µ-capture IgM EIA.  
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Figure 17. SDS-PAGE gel of the produced CuV VLPS after 2x ultracentrifugation. From left to right: 
Precision Plus Protein™ Dual Color Standard (Bio-Rad), A: the old batch of the CuV VLPs, B. batch 
no. 1 of the new CuV VLPs and C. new batch no.2 of the new CuV VLPs. The correct size for the 
CuV VP2 VLP is ~65 kDa.  
 
The performance of the produced biotinylated and non-biotinylated CuV VLPs was tested in CuV 
IgG EIA with no competition using biotinylated antigen concentrations of 80 ng and 160 ng per well. 
The CuV VLPs were tested in a competition assay with homologous and heterologous competition 
using non-biotinylated CuV and BuV2 VLPs, respectively (Väisänen et al., 2016). Serum samples 
GoSe and VaPa, which are known to be CuV positive and negative, respectively, were used to test 
the CuV VLPs. In addition, Sample M60, which is known to be CuV IgG cross-reactive and BuV1-
3 IgG-positive, was included in the test panels. The CuV VLPs performed as expected (Figure 18.). 
For example, Sample GoSe gave absorbance values from 4.06 to 3.74 in CuV IgG EIA without 
competition, VLP concentrations 80 ng and 160 ng/well, respectively. When Sample GoSe was 
assigned to homologous competition with non-biotinylated CuV VLPs the absorbance value was 
blocked to 0.10.  
37 kDa 
50 kDa 
75 kDa 
A. B. C. 
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Figure 18: The new batch of biotinylated and non-biotinylated CuV VLPs in CuV IgG EIA. 
Absorbance was measured at 450 nm (y-axis) and the results are grouped by the sample. The black 
color marks the CuV IgG EIA with no competition. The red color marks the CuV IgG competition 
EIA panel.  
 
To test whether the ambiguous results in the CuV µ-capture IgM EIA with competition were related 
to the batch of CuV VLPs used, the new batch of CuV VLPs were tested in CuV µ-capture IgM EIA 
with competition, homologous and heterologous (BuV1-3) competition treatments. The competition 
assay was performed using six serum samples from the Iran cohort: N18, N27, N43, N44, N67 and 
N101. The samples gave a mean absorbance value of 0.192 with the new batch of CuV VLPs in the 
no competition treatment (Figure 19.). The pre-incubation with the new batch of non-biotinylated 
CuV VLPs reduced the absorbance value by approximately 40 % in homologous competition µ-
capture IgM EIA. Overall, the new batch of CuV VLPs gave significantly lower absorbance values 
when compared to the absorbance values gained with the old batch of CuV VLPs (Figure 15.).  
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Figure 19. The new batch of CuV VLPs in IgM µ-capture EIA tested with six samples in the Iran 
cohort. The circle with no fill marks for the no competition treatment, circle with fill mars for the 
homologous competition treatment and the cross marks for heterologous competition with BuV1-3. 
The assay was performed with 10 ng per well of biotinylated antigen and 30 µg/ml of the non-
biotinylated antigen 
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5. DISCUSSION 
Several new viruses have been identified during the last few decades due to the developments in the 
field of next generation sequencing. Parvoviruses BuV, TuV and CuV were discovered in the last 
seven years in human samples (Phan et al., 2012; Phan et al., 2014; Phan et al., 2016). BuV DNA 
has been found in stool samples and it is associated with gastrointestinal illnesses (Phan et al., 2012; 
Väisänen et al., 2014, 2016; Yahiro et al., 2014; A. Altay et al., 2015; Chieochansin, 2015; Ayouni 
et al., 2016). CuV is suggested to have a connection to skin cancers and CuV DNA has been found 
in skin biopsies of patients with CTCL or melanoma (Phan et al., 2016; Mollerup et al., 2017; Kreuter 
et al., 2018, Väisänen et al., 2018). IgG EIA has been developed for BuV1-3, CuV and TuV and 
striking differences in geographical distribution for BuV has been identified (Väisänen et al., 2016, 
2018).  There were two main aims for this thesis work: to screen three stool sample cohorts with in-
house BuV, TuV, CuV multiplex qPCR and to develop an IgM EIA for human protoparvoviruses. 
5.1. TuV and CuV were found in stool since the discovery of the viruses 
This is the first study to identify TuV DNA, since its discovery in 2014 in feces of 18-months-old 
girl, with unexplained diarrhea (Phan et al., 2014). After the discovery, TuV IgG has been reported 
in two subjects in Finland, but no TuV DNA has been searched nor found in human stool (Väisänen 
et al., 2016, 2018). In 2016, a sequence resembling TuV DNA was found in seal furs in South 
America  (Kluge et al., 2016), but there is no other mention of the virus DNA in scientific publications 
since 2014. In this study, TuV DNA was found in 0.25 % of the analyzed stool samples (n=407). The 
TuV DNA-positive amplicon had a total of 6 mismatches, when compared to the TuV plasmid 
standard, thus contamination from the plasmid standard can be ruled out. The TuV DNA-positive 
sample was from the HUSLAB b cohort, but no diarrhea causing bacteria had been found from the 
sample by HUSLAB. The patient had been travelling in Turkey and Jamaica, but no additional 
information was available from this patient.  
CuV DNA was found in 2.9 % of the stool samples (n=407) by qPCR in this study and the results 
were verified by sequencing. Before this, CuV DNA has been described in  skin biopsies of CTCL, 
organ transplant and melanoma patients (Phan et al., 2016; Väisänen et al., 2019; Mollerup et al., 
2017). CuV is one of the newest members of the Parvoviridae family and due to its possible link to 
cancer it has quickly become the most studied emerging parvovirus. During 2018 six papers 
(pubmed.gov) addressing CuV were published.  
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In the case of BuV, virus DNA was found in one stool sample (0.2 %) in the Malawi cohort. Since 
its discovery in 2012 (Phan et al., 2012) BuV has been repeatedly found by PCR-based methods in 
stool samples and the virus has been linked to gastrointestinal illnesses. BuV DNA was also recently 
found in urban streams of the capital of Ecuador by metagenomics (Guerrero-Latorre et al., 2018). 
Overall, the reported viral loads as well as the reported prevalence of detected BuV DNA has been 
relatively low with median prevalence of 1,8 % (Phan et al., 2012, Altay et al., 2015; Chieochansin 
et al., 2015; Smits et al. 2014; Väisänen et al.2014, 2016; Yahiro et al. 2014).  
5.1.1. Primer cross reactivity in the multiplex qPCR 
Primer-cross reactivity was observed during the BuV, TuV, CuV multiplex qPCR analyses. Samples 
54 and 13FV10 gave positive qPCR signals for CuV and TuV, respectively, but were deemed false 
positives based on the sequence analysis. Sample 13FV10 derived amplicon was identified as 
Alistipes shahii bacteria and, interestingly, the amplicon from Sample 54 was identified as BuV (2 or 
3) based on sequence and BLAST analysis.  
The BuV, TuV, CuV multiplex qPCR reaction mixture has a total of 6 primers and 3 probes. Despite 
the careful assay design, the possibility of amplifying a non-target nucleotide sequence exists. In this 
study, from a total of 407 qPCR analyzed stool samples, 0.49 % gave a false positive signal, which 
results in assay specificity of 99.51 %. Further optimizing of the assay might be possible to increase 
specificity. With that being said, the BuV, CuV, TuV multiplex qPCR assay is highly sensitive, the 
reported limit of detection (LOD) of the assay is at ≤ 10 copies/µL (Väisänen et al., 2018), but as was 
seen in this study the assay can detect copy numbers as low as 1 copy/µL. In the case of BuV, TuV, 
and CuV the detected viral loads are normally extremely low and the assay sensitivity  might be more 
important than absolute specificity. 
5.2. The protoparvovirus IgM EIA requires more optimization 
In addition to qPCR screening of the stool sample cohorts, the other aim of this thesis work was to 
develop a human protoparvovirus µ-capture IgM EIA using BuV1 as an example. Several steps were 
taken to optimize and later to troubleshoot the assay and its components. The protoparvovirus µ-
capture IgM EIA development was not finalized in this study. The assay requires further optimization, 
before it can be used for sample screening. However, this study offers a good base for future assay 
development. Acquiring a positive control, for example immunized rabbit sera or BuV1-3 or CuV 
IgM-positive serum sample from a patient, is crucial for further assay design. In addition to that, the 
effect of VLP-batch variability and storage of the VLPs on the IgM EIA should be more carefully 
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studied. The used biotinylated BuV1 VLPs in this study had been stored for approximately two years 
and thawed several times, this can damage the structure of the VLPs. It could be worth investigating 
the storage conditions, how the storage affects the VLPs and could the storage and freezing solution 
be improved. Adding trehalose or sucrose to the mix can improve the stability of the capsids during 
long-time storage (Wang et al., 2017; Lan et al., 2018).  Based on this study all samples in the Iran 
serum sample cohort (n=118) were identified IgM-negative for BuV1.  
5.3.Conclusions and future prospects  
Tools to develop assays able to detect viral DNA or specific antibodies are in the core, when studying 
emerging viruses, the distribution, what kind symptoms the viruses cause and what kind of risk they 
pose to human health. BuV has been detected in Europe, Africa and Asia, and the BuV DNA-positive 
fecal sample from Malawi presented in this study further on supports the theory that the virus has 
spread globally. In this study, CuV DNA was found from all the stool sample cohorts. This supports 
the hypothesis of CuV having a possible role in gastrointestinal illnesses (Phan et al., 2016; Väisänen 
et al., 2017). Since CuV DNA has now been found from skin biopsies as well as from stool samples, 
it can speculated, whether the virus can cause systemic infections. Therefore, CuV studies should not 
be limited to cancer patients only. TuV findings have been scarce and this study is the first to identify 
TuV DNA since the discovery of the virus. The detected viral load was low and can be, in theory, 
derived from a dietary or other contamination. More research on TuV is needed to verify its role as a 
human virus. TuV is phylogenetically very closely related to rodent viruses and it would be interesting 
to screen animal derived samples using the BuV, TuV, CuV multiplex qPCR. 
Catching an acute BuV, CuV or TuV infection is at the heart of the emerging human protoparvovirus 
research. Since it is now known that there is differences in BuV IgG distribution globally (high 
seroprevalence in Middle East and Kenya) (Väisänen et al., 2018), the search of acute infections can 
be pinpointed to a certain geographical area. The development of a sensitive and specific 
protoparvovirus IgM EIA will be continued. When successful, the IgM serology can be combined 
with the highly sensitive BuV, TuV, CuV qPCR assay in the future. The combination of these assays 
will shed more light on human protoparvovirus pathogenity, distribution, symptoms and possibly 
transmission.  
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